Error processing SSI file
Weekly Report: Influenza Summary Update
2008-2009 Influenza Season Week 23 ending June 13, 2009All data are preliminary and may change as more reports are received.
On June 11, the World Health Organization raised the pandemic alert level from Phase 5 to Phase 6 indicating that an influenza pandemic is underway. The novel influenza A (H1N1) virus now will be referred to as “pandemic H1N1 influenza virus.”
During week 23 (June 7-13, 2009), influenza activity decreased in the United States, however, there were still higher levels of influenza-like illness than is normal for this time of year.
- Two thousand seven hundred sixty-five (38.7%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive for influenza.
- Over 98% of all subtyped influenza A viruses being reported to CDC were pandemic influenza A (H1N1) viruses.
- The proportion of deaths attributed to pneumonia and influenza (P&I) was slightly above the epidemic threshold.
- One influenza-associated pediatric death was reported and was associated with pandemic influenza A (H1N1) virus infection.
- The proportion of outpatient visits for influenza-like illness (ILI) was below the national baseline. One of the 10 surveillance regions reported ILI above their region-specific baseline.
- Eleven states reported geographically widespread influenza activity, six states and Puerto Rico reported regional influenza activity, the District of Columbia and 13 states reported local influenza activity, and 20 states reported sporadic influenza activity.
HHS Surveillance Regions*
|Data for current week||Data cumulative for the season|
|Out-patient ILI†||% positive for flu‡||Number of jurisdictions reporting regional or widespread activity§||A (H1)||A (H3)||Novel A (H1N1)||A (could not be subyped)¥||A(Unsub-typed)||B||Pediatric Deaths|
|Nation||Normal||38.7 %||18 of 52||7,824||2,170||12,316||428||13,079||10,397||71|
|Region I||Normal||38.3 %||4 of 6||520||151||1,542||13||1,302||800||1|
|Region II||Elevated||35.5 %||3 of 3||277||137||592||16||1,492||711||9|
|Region III||Normal||37.5 %||3 of 6||1.313||213||1,353||0||669||1,360||9|
|Region IV||Normal||19.7 %||2 of 8||828||117||351||41||1,897||1,211||6|
|Region V||Normal||52.6 %||2 of 6||1,653||190||5,726||129||555||1,326||11|
|Region VI||Normal||14.1 %||0 of 5||768||165||898||5||4,079||2,608||14|
|Region VII||Normal||12.0 %||0 of 4||498||60||159||113||450||529||0|
|Region VIII||Normal||29.7 %||1 of 6||526||216||745||57||1,501||498||6|
|Region IX||Normal||12.9 %||3 of 4||1,061||627||680||22||798||690||14|
|Region X||Normal||23.2 %||0 of 4||380||294||270||32||336||664||1|
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE;
Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA)
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline
‡ National data are for current week; regional data are for the most recent three weeks
§ Includes all 50 states, the District of Columbia, and Puerto Rico
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are pandemic A (H1N1) influenza viruses upon further testing
U.S. Virologic Surveillance:
WHO and NREVSS collaborating laboratories located in all 50 states and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United States. On April 15 and 17, 2009, CDC confirmed the first two cases of pandemic influenza A (H1N1) virus in the United States. As of June 19, 2009, 21,449 confirmed and probable infections with pandemic influenza A (H1N1) virus and 87 deaths (24 in individuals less than 25 years and 63 deaths in adults 25 years of age older) have been identified by CDC and state and local public health departments. Reporting of pandemic influenza A (H1N1) viruses by U.S. WHO collaborating laboratories began during week 17 (week ending May 2, 2009). The results of tests performed during the current week are summarized in the table below.
|No. of specimens tested||7,149|
|No. of positive specimens (%)||2,765 (38.7%)|
|Positive specimens by type/subtype|
|Influenza A||2,759 (99.8%)|
|A (pandemic H1N1)||2,263 (82.0%)|
|A (unable to subtype)||24 (0.9%)|
|A (H3)||21 (0.8%)|
|A (H1)||22 (0.8%)|
|Influenza B||6 (0.2%)|
During week 23, seasonal influenza A (H1), A (H3), and B viruses co-circulated at low levels with pandemic influenza A (H1N1). Over 98% of all subtyped influenza A viruses being reported to CDC this week were pandemic influenza A (H1N1) viruses.
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS collaborating laboratories may be due in part to changes in testing practices by health care providers, triaging of specimens by public health laboratories, an increase in the number of specimens collected from outbreaks, and other factors.
View WHO-NREVSS Regional Bar Charts| View Chart Data | View Full Screen
CDC has antigenically characterized 1,635 seasonal human influenza viruses [947 influenza A (H1), 171 influenza A (H3) and 517 influenza B viruses] collected by U.S. laboratories since October 1, 2008, and 144 pandemic influenza A (H1N1) viruses.
All 947 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 2008-09 influenza vaccine (A/Brisbane/59/2007). All 171 influenza A (H3N2) viruses are related to the A (H3N2) vaccine component (A/Brisbane/10/2007).
All 144 pandemic influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference virus selected by WHO as a potential candidate for pandemic influenza A (H1N1) vaccine.
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-five influenza B viruses tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 452 viruses belong to the B/Victoria lineage and are not related to the vaccine strain.
Data on antigenic characterization should be interpreted with caution given that antigenic characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference ferret antisera and results may not correlate with clinical protection against circulating viruses provided by influenza vaccination.
Annual influenza vaccination is expected to provide the best protection against those virus strains that are related to the vaccine strains, but limited to no protection may be expected when the vaccine and circulating virus strains are so different as to be from different lineages, as is seen with the two lineages of influenza B viruses. Antigenic characterization of pandemic influenza A (H1N1) viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with seasonal influenza vaccine.
Since October 1, 2008, 988 seasonal influenza A (H1N1), 172 influenza A (H3N2), and 529 influenza B viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). Nine hundred ninety-one seasonal influenza A (H1N1) and 179 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). One hundred eighty-eight pandemic influenza A (H1N1) viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). One hundred forty-two pandemic influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). The results of antiviral resistance testing performed on these viruses are summarized in the table below.
|Isolates tested (n)||Resistant Viruses,
|Isolates tested (n)||Resistant Viruses, Number (%)|
|Seasonal Influenza A (H1N1)||988||983 (99.5%)||0 (0)||991||6 (0.6%)|
|Influenza A (H3N2)||172||0 (0)||0 (0)||179||179 (100%)|
|Influenza B||529||0 (0)||0 (0)||N/A*||N/A*|
|Novel Influenza A (H1N1)||188||0 (0)||0 (0)||142||142 (100%)|
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with confirmed, probable or suspected cases of pandemic influenza A (H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza complications. The pandemic influenza A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine. Additional information on antiviral recommendations for treatment and chemoprophylaxis of pandemic influenza A (H1N1) infection is available at http://www.cdc.gov/h1n1flu/recommendations.htm
In areas that continue to have seasonal influenza activity, especially those with circulation of oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human influenza A (H1N1) virus infection.
Pneumonia and Influenza (P&I) Mortality Surveillance
During week 23, 7.0% of all deaths reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is slightly above the epidemic threshold of 6.9% for week 23.
View Full Screen
Influenza-Associated Pediatric Mortality
One influenza-associated pediatric death was reported to CDC during week 23 (Arizona). This death was associated with a pandemic influenza A (H1N1) virus infection. The death reported this week occurred during week 23 (the week ending June 13, 2009). Since September 28, 2008, CDC has received 71 reports of influenza-associated pediatric deaths that occurred during the current influenza season, six of which were due to pandemic influenza A (H1N1) virus infections.
Of the 34 children who had specimens collected for bacterial culture from normally sterile sites, 14 (41.2%) were positive; Staphylococcus aureus was identified in nine (64.3%) of the 14 children. One of the three children with confirmed pandemic influenza A (H1N1) infection had a specimen collected from a normally sterile site; bacterial cultures were negative. Four of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant. Twelve (85.7%) of the 14 children with bacterial coinfections were five years of age or older and 10 (71.4%) of the 14 children were 12 years of age or older. An increase in the number of influenza-associated pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza season. In January 2008, interim testing and reporting recommendations were released regarding influenza and bacterial coinfections in children and are available at (http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268).
View Full Screen
Laboratory-confirmed influenza-associated hospitalizations are monitored in two population-based surveillance networks: the New Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).
During October 12, 2008 to May 30, 2009, the preliminary laboratory-confirmed influenza-associated hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. Because of case identification methods utilized in this study, there is a delay from the date of hospitalization to the date of report.
View Full Screen
During April 15, 2009 – June 13, 2009, the following preliminary laboratory-confirmed overall influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, and confirmed Pandemic H1N1):
Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 0.92, 0.22, and 0.16 per 10,000, respectively. Rates for adults aged 18-49 years, 50-64 years, and = 65 years, the overall flu rates were 0.07, 0.09, and 0.23 per 10,000, respectively.
*This value represents an age group-specific average influenza rate from October 1 to April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
**Note: The scales for the 0-23 month and the >= 65 years age groups differ from other age groups.
View Full Screen
Outpatient Illness Surveillance:
Nationwide during week 23, 1.8% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%.
View ILINet Regional Charts | View Chart Data |View Full Screen
On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 4.7%. One of the 10 surveillance regions reported an ILI percentage above their region specific baseline (Region II). ILI decreased during week 23 in six of 10 regions compared to week 22.
Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:
The influenza activity reported by state and territorial epidemiologists indicates geographic spread of both seasonal influenza and pandemic influenza A (H1N1) viruses and does not measure the severity of influenza activity.
During week 23, the following influenza activity was reported:
- Widespread influenza activity was reported by 11 states (Arizona, Connecticut, Delaware, Hawaii, Maine, New Jersey, New York, Pennsylvania, Rhode Island, Utah, and Virginia).
- Regional influenza activity was reported by Puerto Rico and six states (California, Georgia, Illinois, Massachusetts, Minnesota, and South Carolina).
- Local influenza activity was reported by the District of Columbia and 13 states (Alabama, Colorado, Maryland, Michigan, New Mexico, North Carolina, Oklahoma, Tennessee, Texas, Vermont, West Virginia, Wisconsin, and Wyoming).
- Sporadic activity was reported by 20 states (Alaska, Arkansas, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, North Dakota, Ohio, Oregon, South Dakota, and Washington).
A description of surveillance methods is available at:
- Page last updated June 19, 2009.